Literature DB >> 26643565

Improvement of Atrial and Ventricular Remodeling with Low Atrial Fibrillation Burden after Hybrid Ablation of Persistent Atrial Fibrillation.

Janez Toplisek1, Andrej Pernat1, Nada Ruzic2, Boris Robic2, Matjaz Sinkovec1, Marta Cvijic1, Borut Gersak2.   

Abstract

BACKGROUND: An endoscopic transdiaphragmatic epicardial radiofrequency ablation procedure combined with percutaneous endocardial radiofrequency ablation--a hybrid procedure--is a potentially curative treatment option for patients with persistent atrial fibrillation (AF). Long-term effects of arrhythmia elimination on atrial and ventricular remodeling are not completely understood. Therefore, the aim of our study was to quantify echocardiographic structural and functional changes of the left atrium (LA) and left ventricle (LV) following a hybrid procedure. METHODS AND
RESULTS: Thirty-seven consecutive patients with symptomatic drug refractory persistent AF underwent a hybrid procedure to achieve complete pulmonary vein and LA posterior wall electrical isolation. AF burden was measured using an insertable electrocardiographic (ECG) monitor. Patients were divided into responders to ablation and nonresponders according to postoperative AF burden at 12-month follow-up (responder < 0.5% vs nonresponder ≥ 0.5%). Median AF burden was 0.32 (0.04-27.5)% for all patients. In responders (19/37 patients), significant echocardiographic reduction of LA volume index from 47 to 41 mL/m(2) (P < 0.05) and improvement of LA function parameters (LA stiffness from 73.3 to 41.3 [P < 0.05], LA emptying fraction from 21% to 45% [P < 0.05], LA global longitudinal strain from 11.2% to 18.8% [P < 0.5]) was documented. In addition, LV systolic function significantly improved in comparison with nonresponders.
CONCLUSION: Hybrid ablation of persistent AF achieved stable sinus rhythm in a significant proportion of patients, as evidenced by continuous ECG monitoring, resulting in important LA and LV reverse remodeling after 12 months.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial fibrillation; hybrid minimally invasive surgical ablation; insertable cardiac monitoring; left atrial and ventricular remodeling

Mesh:

Year:  2016        PMID: 26643565     DOI: 10.1111/pace.12791

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  Posterior Wall Isolation for Atrial Fibrillation: Effects on Echocardiographic Parameters of cardiac function.

Authors:  Xin Zhang; Neil Beri; Pankaj Malhotra; Rakhee Makhija; Eric Nordsieck; Adam Oesterle; Dali Fan; Nayereh Pezeshkian; Uma Srivatsa
Journal:  J Atr Fibrillation       Date:  2020-10-31

2.  Targeting Bachmann's bundle in hybrid ablation for long-standing persistent atrial fibrillation: a proof of concept study.

Authors:  Giuseppe De Martino; Giuseppe Nasso; Alessio Gasperetti; Marco Moscarelli; Carmine Mancusi; Giuseppe Della Ratta; Claudia Calvanese; Gianfranco Mitacchione; Raffaele Bonifazi; Nicola Di Bari; Enrico Vassallo; Marco Schiavone; Mario Gaudino; Giovanni B Forleo; Giuseppe Speziale
Journal:  J Interv Card Electrophysiol       Date:  2021-03-08       Impact factor: 1.759

3.  Hybrid ablation for atrial fibrillation: A systematic review and meta-analysis.

Authors:  Jason A Varzaly; Dennis H Lau; Darius Chapman; James Edwards; Michael Worthington; Prashanthan Sanders
Journal:  JTCVS Open       Date:  2021-07-16

4.  A three-year longitudinal study of the relation between left atrial diameter remodeling and atrial fibrillation ablation outcome.

Authors:  Hui-Ling Lee; Yi-Ting Hwang; Po-Cheng Chang; Ming-Shien Wen; Chung-Chuan Chou
Journal:  J Geriatr Cardiol       Date:  2018-07       Impact factor: 3.327

5.  Catheter, surgical, or hybrid procedure: what future for atrial fibrillation ablation?

Authors:  Giuseppe Santarpino; Giuseppe Speziale; Giuseppe Nasso; Roberto Lorusso; Marco Moscarelli; Giuseppe De Martino; Angelo M Dell'Aquila; Arash Motekallemi; Nicola Di Bari; Ignazio Condello; Pasquale Mastroroberto
Journal:  J Cardiothorac Surg       Date:  2021-06-26       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.